New model addresses patient harm and healthcare costs associated with IV therapy.
- IVWatch and Aon have collaborated on a new ROI model.
- The model aims to reduce costs related to patient harm.
- It specifically targets issues in IV therapy management.
IVWatch and Aon are addressing the costly issue of patient harm related to intravenous (IV) therapy through a newly developed Return on Investment (ROI) model. This initiative comes in response to the significant financial and health impacts of underreported patient harm incidents, particularly associated with IV administration. By focusing on optimizing patient care, the model seeks to not only enhance safety in IV therapy but also improve overall healthcare costs.
The new ROI model aims to provide clinical and financial insights for healthcare facilities by quantifying the risks of patient harm during IV therapy. It allows institutions to better understand the financial implications and long-term benefits of implementing effective IV safety measures. IVWatch aims to empower organizations to evaluate and mitigate these risks, aligning with Aon's expertise in risk management and patient safety.
This collaboration highlights a critical focus on patient safety and aims to provide frameworks that can potentially lower the prevalence of costly healthcare events. By emphasizing the importance of addressing patient harm, particularly in the context of IV therapy, both organizations hope to set a precedent for better quality of care in the healthcare industry.
